Table 2 Summary statistics of GC doses and duration of use per patient during follow-up and in the 12 months prior to study entry for those patients ever prescribed GCs (n = 7777)

Measure^*

Median

IQR

Median

IQR

Duration of follow-up (years)

5.29

2.62–8.58

-

-

Cumulative duration of GC use (years)

0.80

0.15–2.56

0.23

0.05–0.67

Proportion of follow-up time on GCs (%)

26.3

3.8–70.0

22.7

5.4–67.2

Average dose^** (mg)

7.5

5–15.3

10

5–20

Lowest dose^** (mg)

5

2.5–7.5

5

3–15

Highest dose^** (mg)

15

7.5–30

15

6–30